Biosimilars Market by Product (Insulin, rhGH, Granulocyte colony-stimulating factor, Interferon, Erythropoietin, Etanercept, Monoclonal antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, and Enoxaparin Sodium), By Manufacturing (In-house, Contract) & Indication (Offsite Treatment, Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease, Blood Disorders, Infectious Disease, and Other Diseases), By Geography (North America, Europe, APAC, and RoW) - Global Opportunity Analysis and Industry Forecast up to 2026
- July, 2020
- Domain: Healthcare - Pharmaceuticals
Pages:
85
Tables:
80
Charts:
40
Regions/Countries:
4 / 9
Companies:
20
Enquiry Hours:
10
- Get Free 10% Customization in this Report
Biosimilars or follow-on-biologics are the "duplicated" and authorized variants of those reference biologics that have experienced patent expiration. Biosimilars improvement and approval with reference biologics is a significant part of the general advancement and development process. Guidelines for biosimilars assume an essential job in keeping up the suitability and harmony among unique and biosimilars items. Different regulatory specialists, for example, EMA and FDA effectively control Biosimilars commercialization and advancement.
Research Methodology:
The biosimilars market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:
The market is driven by factors such as the rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs. However, market growth is limited by manufacturing complexities and resistance from biological manufacturers. Furthermore, the growth of the biosimilars market is hampered with multiple factors including the lack of regulatory guidelines, consumers’ brand preferences, the reluctance of physicians to prescribed biosimilars, and the high capital required for research and development.
Based on the parameter of manufacturing, the market of Biosimilars is segmented into two segments:
- In-house manufacturing
- Contract manufacturing
The in-house manufacturing segment makes up for the larger market share, while the contract manufacturing segment is expected to witness the highest CAGR during the forecasting period.
Based on the product, the biosimilars market monoclonal antibody industry is prominently segmented into trastuzumab, infliximab, rituximab, adalimumab, and other monoclonal antibodies. The infliximab segment accounted for the largest biosimilars market share in 2019. The growing prevalence of autoimmune diseases drives market growth.
Based on the indication, the market is segregated on the basis of:
- Oncology
- Blood Disorder
- Offsite Treatment
- Infectious Diseases
- Chronic Diseases
- Autoimmune Disease
- Other Diseases
The oncology segment accounts for a major share of the biosimilars market. The large share of this segment can be attributed to the high incidence of cancer across the globe.
Some of the major players in the domain of Biosimilars are Probiomed, Boehringer Ingelheim, Apotex, Fresenius Kabi, Gedeon Richter, Mabxience, Amega Biotech, Biocad, Coherus Biosciences, Stada Arzneimittel Ag, Dr. Reddy’s Laboratories, Mylan, Samsung Biologics, Amgen, Biocon, Celltrion, Teva Pharmaceutical, Eli Lilly, Pfizer, and Sandoz.
By Geography, the market of Biosimilars is further classified into North America, Europe, the Asia Pacific, and the rest of the World. North America accounted for the largest share. There are two important factors which are the driving forces behind the growth of Biosimilars market giving it CAGR of 23.9% during the forecast period. These two factors are:
- Lower pricing than competing biologics
- Rising incidence of chronic diseases
There are a lot of opportunities in emerging countries and this report will help in understanding the current market dynamics, changing needs, and innovations that might be needed to make the user experience enriching.
- This report would be the foundation for any research on the Biosimilars, vendor capabilities, SWOT of the sensors, and organized framework for data analysis for further advanced innovation.
- This piece of the report would be the backbone for exhaustive research and a tool for the upcoming innovations and technologies. This gives an idea about the major competitors in the market, their journey, and the competitive edge which one should have to beat other players in the market.
- The report is having a qualitative analysis of the Biosimilars market and the opportunity which can be leveraged by the market in the current scenario
- The market report would be delving into deep insights regarding the technological innovations
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.3. PEST Analysis
3.4. Porter Five Forces
3.5. Related Markets
4. Market characteristics
4.1. Market Evolution
4.2. Market Trends and Impact
4.3. Advantages/Disadvantages of Market
4.4. Regulatory Impact
4.5. Market Offerings
4.6. Market Segmentation
4.7. Market Dynamics
4.7.1. Drivers
4.7.2. Restraints
4.7.3. Opportunities
4.8. DRO - Impact Analysis
5. Indication: Market Size & Analysis
5.1. Overview
5.2. Autoimmune Disease
5.3. Blood Disorders
5.4. Infectious Disease
5.5. Chronic Disorder
5.6. Oncology
5.7. Offsite Treatment
5.8. Other Diseases
6. Type of Manufacturing: Market Size & Analysis
6.1. Overview
6.2. In-House Manufacturing
6.3. Contract Manufacturing
7. Product: Market Size & Analysis
7.1. Overview
7.2. Insulin
7.3. Recombinant human growth hormone (rhGH)
7.4. Granulocyte colony-stimulating factor
7.5. Interferon
7.6. Erythropoietin
7.7. Etanercept
7.8. Monoclonal antibodies
7.8.1. Rituximab
7.8.2. Infliximab
7.8.3. Adalimumab
7.8.4. Trastuzumab
7.9. Follitropin
7.10. Glucagon
7.11. Calcitonin
7.12. Teriparatide
7.13. Enoxaparin Sodium
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.3. Mergers and Acquisitions, Legal, Awards, Partnerships
9.4. Product Launches and execution
10. Vendor Profiles
10.1. Dr. Reddy’s Laboratories
10.1.1. Overview
10.1.2. Product Offerings
10.1.3. Geographic Revenue
10.1.4. Business Units
10.1.5. Developments
10.1.6. SWOT Analysis
10.1.7. Business Strategy
10.2. Stada Arzneimittel Ag
10.2.1. Overview
10.2.2. Product Offerings
10.2.3. Geographic Revenue
10.2.4. Business Units
10.2.5. Developments
10.2.6. SWOT Analysis
10.2.7. Business Strategy
10.3. Coherus Biosciences
10.3.1. Overview
10.3.2. Product Offerings
10.3.3. Geographic Revenue
10.3.4. Business Units
10.3.5. Developments
10.3.6. SWOT Analysis
10.3.7. Business Strategy
10.4. Biocad
10.4.1. Overview
10.4.2. Product Offerings
10.4.3. Geographic Revenue
10.4.4. Business Units
10.4.5. Developments
10.4.6. SWOT Analysis
10.4.7. Business Strategy
10.5. Amega Biotech
10.5.1. Overview
10.5.2. Product Offerings
10.5.3. Geographic Revenue
10.5.4. Business Units
10.5.5. Developments
10.5.6. SWOT Analysis
10.5.7. Business Strategy
10.6. Probiomed
10.6.1. Overview
10.6.2. Product Offerings
10.6.3. Geographic Revenue
10.6.4. Business Units
10.6.5. Developments
10.6.6. SWOT Analysis
10.6.7. Business Strategy
10.7. Boehringer Ingelheim
10.7.1. Overview
10.7.2. Product Offerings
10.7.3. Geographic Revenue
10.7.4. Business Units
10.7.5. Developments
10.7.6. SWOT Analysis
10.7.7. Business Strategy
10.8. Apotex
10.8.1. Overview
10.8.2. Product Offerings
10.8.3. Geographic Revenue
10.8.4. Business Units
10.8.5. Developments
10.8.6. SWOT Analysis
10.8.7. Business Strategy
10.9. Fresenius Kabi
10.9.1. Overview
10.9.2. Product Offerings
10.9.3. Geographic Revenue
10.9.4. Business Units
10.9.5. Developments
10.9.6. SWOT Analysis
10.9.7. Business Strategy
10.10. Gedeon Richter
10.10.1. Overview
10.10.2. Product Offerings
10.10.3. Geographic Revenue
10.10.4. Business Units
10.10.5. Developments
10.10.6. SWOT Analysis
10.10.7. Business Strategy
11. Companies to Watch
11.1. Mabxience
11.1.1. Overview
11.1.2. Market
11.1.3. Business Strategy
11.2. Sandoz
11.2.1. Overview
11.2.2. Market
11.2.3. Business Strategy
11.3. Pfizer
11.3.1. Overview
11.3.2. Market
11.3.3. Business Strategy
11.4. Eli Lilly
11.4.1. Overview
11.4.2. Market
11.4.3. Business Strategy
11.5. Teva Pharmaceutical
11.5.1. Overview
11.5.2. Market
11.5.3. Business Strategy
11.6. Celltrion
11.6.1. Overview
11.6.2. Market
11.6.3. Business Strategy
11.7. Biocon
11.7.1. Overview
11.7.2. Market
11.7.3. Business Strategy
11.8. Amgen
11.8.1. Overview
11.8.2. Market
11.8.3. Business Strategy
11.9. Samsung Biologics
11.9.1. Overview
11.9.2. Market
11.9.3. Business Strategy
11.10. Mylan
11.10.1. Overview
11.10.2. Market
11.10.3. Business Strategy
12. Analyst Opinion
13. Annexure
13.1. Report Scope
13.2. Market Definitions
13.3. Research Methodology
13.3.1. Data Collation and In-house Estimation
13.3.2. Market Triangulation
13.3.3. Forecasting
13.4. Report Assumptions
13.5. Declarations
13.6. Stakeholders
13.7. Abbreviations
- GLOBAL BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR AUTOIMMUNE DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR BLOOD DISORDERS, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR INFECTIOUS DISEASE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR CHRONIC DISORDER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR ONCOLOGY, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR OFFSITE TREATMENT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR OTHER, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR CONTRACT MANUFACTURING, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR INSULIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR RHGH, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR GRANULOCYTE COLONY STIMULATING FACTOR, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR INTERFERON, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR ERYTHROPOIETIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR ETANERCEPT, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR FOLLITROPIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR GLUCAGON, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR CALCITONIN, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR TERIPARATIDE, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- GLOBAL BIOSIMILARS MARKET VALUE FOR ENOXAPARIN SODIUM, BY GEOGRAPHY, 2020-2026 (USD BILLION)
- NORTH AMERICA BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
- NORTH AMERICA BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
- NORTH AMERICA BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
- NORTH AMERICA BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
- EUROPE BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
- EUROPE BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
- EUROPE BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
- EUROPE BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
- ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
- ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
- ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
- ASIA PACIFIC BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
- REST OF WORLD BIOSIMILARS MARKET VALUE, BY COUNTRY, 2020-2026 (USD BILLION)
- REST OF WORLD BIOSIMILARS MARKET VALUE, BY INDICATION, 2020-2026 (USD BILLION)
- REST OF WORLD BIOSIMILARS MARKET VALUE, BY TYPE OF MANUFACTURING, 2020-2026 (USD BILLION)
- REST OF WORLD BIOSIMILARS MARKET VALUE, BY PRODUCT, 2020-2026 (USD BILLION)
- DR. REDDY’S LABORATORIES: OVERVIEW
- DR. REDDY’S LABORATORIES: STRATEGIC SNAPSHOT
- DR. REDDY’S LABORATORIES: BUSINESS FOCUS
- DR. REDDY’S LABORATORIES: PRODUCT/SERVICE PORTFOLIO
- STADA ARZNEIMITTEL AG: OVERVIEW
- STADA ARZNEIMITTEL AG: STRATEGIC SNAPSHOT
- STADA ARZNEIMITTEL AG: BUSINESS FOCUS
- STADA ARZNEIMITTEL AG: PRODUCT/SERVICE PORTFOLIO
- COHERUS BIOSCIENCES: OVERVIEW
- COHERUS BIOSCIENCES: STRATEGIC SNAPSHOT
- COHERUS BIOSCIENCES: BUSINESS FOCUS
- COHERUS BIOSCIENCES: PRODUCT/SERVICE PORTFOLIO
- BIOCAD: OVERVIEW
- BIOCAD: STRATEGIC SNAPSHOT
- BIOCAD: BUSINESS FOCUS
- BIOCAD: PRODUCT/SERVICE PORTFOLIO
- AMEGA BIOTECH: OVERVIEW
- AMEGA BIOTECH: STRATEGIC SNAPSHOT
- AMEGA BIOTECH: BUSINESS FOCUS
- AMEGA BIOTECH: PRODUCT/SERVICE PORTFOLIO
- PROBIOMED: OVERVIEW
- PROBIOMED: STRATEGIC SNAPSHOT
- PROBIOMED: BUSINESS FOCUS
- PROBIOMED: PRODUCT/SERVICE PORTFOLIO
- BOEHRINGER INGELHEIM: OVERVIEW
- BOEHRINGER INGELHEIM: STRATEGIC SNAPSHOT
- BOEHRINGER INGELHEIM: BUSINESS FOCUS
- BOEHRINGER INGELHEIM: PRODUCT/SERVICE PORTFOLIO
- APOTEX: OVERVIEW
- APOTEX: STRATEGIC SNAPSHOT
- APOTEX: BUSINESS FOCUS
- APOTEX: PRODUCT/SERVICE PORTFOLIO
- FRESENIUS KABI: OVERVIEW
- FRESENIUS KABI: STRATEGIC SNAPSHOT
- FRESENIUS KABI: BUSINESS FOCUS
- FRESENIUS KABI: PRODUCT/SERVICE PORTFOLIO
- GEDEON RICHTER: OVERVIEW
- GEDEON RICHTER: STRATEGIC SNAPSHOT
- GEDEON RICHTER: BUSINESS FOCUS
- GEDEON RICHTER: PRODUCT/SERVICE PORTFOLIO
Research Framework
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
Market related information is congregated from both primary and secondary sources.
Primary sources
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.
